Jliang
2021-12-22
Please like
FDA puts Gilead's Lenacapavir studies in HIV on hold due to vial quality concerns
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
3
3
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":691807500,"tweetId":"691807500","gmtCreate":1640158999498,"gmtModify":1640158999790,"author":{"id":3578105588635717,"idStr":"3578105588635717","authorId":3578105588635717,"authorIdStr":"3578105588635717","name":"Jliang","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":24,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Please like</p></body></html>","htmlText":"<html><head></head><body><p>Please like</p></body></html>","text":"Please like","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/691807500","repostId":1158404163,"repostType":4,"repost":{"id":"1158404163","kind":"news","pubTimestamp":1640158909,"share":"https://www.laohu8.com/m/news/1158404163?lang=&edition=full","pubTime":"2021-12-22 15:41","market":"us","language":"en","title":"FDA puts Gilead's Lenacapavir studies in HIV on hold due to vial quality concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=1158404163","media":"seekingalpha","summary":"Gilead Sciences(NASDAQ:GILD)announces that the FDA has placed a clinical hold on the use of injectab","content":"<p>Gilead Sciences(NASDAQ:GILD)announces that the FDA has placed a clinical hold on the use of injectable lenacapavir in borosilicate vials in all ongoing clinical studies for HIV treatment and HIV pre-exposure prophylaxis (PrEP).</p>\n<p>The FDA’s clinical hold is due to emerging concerns about the compatibility of vials made of borosilicate glass with lenacapavir solution, which could potentially lead to the formation of sub-visible glass particles in the solution of lenacapavir.</p>\n<p>Dosing of oral formulations of lenacapavir will continue.</p>\n<p>The following are some of the studies that have been placed on clinical hold:</p>\n<p>A Phase 2/3 study to evaluate GS-6207 in combination with an optimized background regimen in people with HIV-1 infection with multidrug resistance.</p>\n<p>A Phase 2 of GS-6207 in combination with other antiretroviral agents in HIV.</p>\n<p>A Phase 1 Study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of Lenacapavir.</p>\n<p>A Phase 3 study to evaluate Lenacapavir, and daily oral emtricitabine/tenofovir alafenamide for PrEP in adolescent girls and young women at risk of HIV.</p>\n<p>A Phase 3 study to evaluate the twice yearly Lenacapavir for HIV PrEP in cisgender men, transgender women, transgender men, and gender non-binary people ≥ 16 years of age at risk for HIV infection.</p>\n<p>A Phase 1b study to evaluate GS-5423 and GS-2872 in combination with GS-6207 in virologically suppressed adults with HIV-1.</p>\n<p>Lenacapavir is Gilead’s investigational long-acting HIV-1 capsid inhibitor in development for the treatment and prevention of HIV-1 infection.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA puts Gilead's Lenacapavir studies in HIV on hold due to vial quality concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA puts Gilead's Lenacapavir studies in HIV on hold due to vial quality concerns\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-22 15:41 GMT+8 <a href=https://seekingalpha.com/news/3782552-fda-puts-gileads-lenacapavir-studies-in-hiv-on-hold-due-to-vial-quality-concerns><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gilead Sciences(NASDAQ:GILD)announces that the FDA has placed a clinical hold on the use of injectable lenacapavir in borosilicate vials in all ongoing clinical studies for HIV treatment and HIV pre-...</p>\n\n<a href=\"https://seekingalpha.com/news/3782552-fda-puts-gileads-lenacapavir-studies-in-hiv-on-hold-due-to-vial-quality-concerns\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学"},"source_url":"https://seekingalpha.com/news/3782552-fda-puts-gileads-lenacapavir-studies-in-hiv-on-hold-due-to-vial-quality-concerns","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1158404163","content_text":"Gilead Sciences(NASDAQ:GILD)announces that the FDA has placed a clinical hold on the use of injectable lenacapavir in borosilicate vials in all ongoing clinical studies for HIV treatment and HIV pre-exposure prophylaxis (PrEP).\nThe FDA’s clinical hold is due to emerging concerns about the compatibility of vials made of borosilicate glass with lenacapavir solution, which could potentially lead to the formation of sub-visible glass particles in the solution of lenacapavir.\nDosing of oral formulations of lenacapavir will continue.\nThe following are some of the studies that have been placed on clinical hold:\nA Phase 2/3 study to evaluate GS-6207 in combination with an optimized background regimen in people with HIV-1 infection with multidrug resistance.\nA Phase 2 of GS-6207 in combination with other antiretroviral agents in HIV.\nA Phase 1 Study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of Lenacapavir.\nA Phase 3 study to evaluate Lenacapavir, and daily oral emtricitabine/tenofovir alafenamide for PrEP in adolescent girls and young women at risk of HIV.\nA Phase 3 study to evaluate the twice yearly Lenacapavir for HIV PrEP in cisgender men, transgender women, transgender men, and gender non-binary people ≥ 16 years of age at risk for HIV infection.\nA Phase 1b study to evaluate GS-5423 and GS-2872 in combination with GS-6207 in virologically suppressed adults with HIV-1.\nLenacapavir is Gilead’s investigational long-acting HIV-1 capsid inhibitor in development for the treatment and prevention of HIV-1 infection.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1070,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":10,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/691807500"}
精彩评论